References
- Biotechnology Industry Organization website. Available at: http://www.bio.org/node/517 [Last accessed 19 December 2011]
- Rathore N, Rajan RS. Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog 2008;24:504-14.
- Sharma B. Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changes. Biotechnol Adv 2007;25:325-31.
- Kleinberg M, Mosdell KW. Current and future considerations for the new classes of biologicals. Am J Health Syst Pharm 2004;61:695-708.
- Kirdar AO, Chen G, Weidner J, et al. Application of near-infrared (NIR) spectroscopy for screening of raw materials used in the cell culture medium for the production of a recombinant therapeutic protein. Biotechnol Prog 2010;26:527-31.
- Lubiniecki A, Volkin DB, Federici M, et al. Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals 2011;39:9-22.
- Luo Y, Chen G. Combined approach of NMR and chemometrics for screening peptones used in the cell culture medium for the production of a recombinant therapeutic protein. Biotechnol Bioeng 2007;97:1654-9.
- Lewis RM, Cosenza ME. Summary of DIA Workshop: Comparability challenges: Regulatory and scientific issues in the assessment of biopharmaceuticals. Drug Inf J 2010;44:485-504.
- Putnam WS, Prabhu S, Zheng Y, et al. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 2010;28:509-16.
- Demonstration of comparability of human biological products, including therapeutic biotechnology-derived products. Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), 1996. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122879.htm [Last accessed 19 December 2011]
- Q5E Comparability of biotechnological/biological products subject to changes in their manufacturing process. Rockville, MD: FDA/Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER), 2005. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm128076.pdf [Last accessed 19 December 2011]
- Comparability of biotechnological/biological products subject to changes in their manufacturing process, Q5E. International Conference on Harmonization/ICH Expert Working Group, 2004. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf [Last accessed 9 March 2012]
- Avonex® Summary Basis for Approval. Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), 2004. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm086056.pdf [Last accessed 19 December 2011]
- Raptiva® European Public Assessment Report Scientific Discussion. London: European Medicines Agency, 2004. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000542/WC500057849.pdf [Last accessed 16 March 2012]
- Meeting of the Endocrinologic and Metabolic Drugs Advisory Commitee (EMDAC) to Evaluate Myozyme (alglucosidase alfa) for the treatment of late onset Pompe Disease. Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4389b1-01-FDA.pdf [Last accessed 19 December 2011]
- Guideline on similar biological medicinal products. London: European Medicines Agency, 2005. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/043704en.pdf [Last accessed 19 December 2011)
- Rossert J. EMEA guidelines on biosimilars and their clinical implications. Kidney Blood Press Res 2007;30(Suppl 1):13-17.
- Scientific Considerations in Demonstrating Biosimilarity to a Reference Protein Product; Draft Guidance; 9 February 2012. Rockville, MD: FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER), 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf [Last accessed 6 March 2012]
- Miletich J, Eich G, Grampp G, et al. Biosimilars 2.0: Guiding principles for a global ‘patients first’ standard. MAbs 2011;3:318-25.
- Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2009;2:i27-36.
- Haag-Weber M, Eckardt KU, Hörl WH, et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012;77:8-17.
- Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: From approval to practice. Eur J Haematol 2010;86:277-88.
- Schellekens H. Recombinant human erythropoietins, biosimilars and immunogenicity. J Nephrol 2008;21:497-502.
- Schellekens H. Assessing the bioequivalence of biosimilars: The Retacrit case. Drug Discov Today 2009;14:495-9.
- Refusal assessment report for Alpheon. London: European Medicines Agency, 2006. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000585/WC500070792.pdf [Last accessed 16 March 2012]
- Withdrawal assessment for Insulin Human Rapid Marvel. London: European Medicines Agency, 2008. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067086.pdf [Last accessed 16 March 2012]
- Withdrawal assessment for Insulin Human Long Marvel. London: European Medicines Agency, 2008. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067170.pdf [Last accessed 16 March 2012]
- Withdrawal assessment for Insulin Human 30/70 Marvel. London: European Medicines Agency 2008. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067169.pdf [Last accessed 16 March 2012]
- Omnitrope® European Public Assessment Report Scientific Discussion. London: European Medicines Agency, 2006. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000607/WC500043692.pdf [Last accessed 16 March 2012]